knowing01 is a MultiomicsAI SaaS Biotech company transforming research with an innovative software platform that automatically contextualizes molecular data at scale. With our in silico-first approach, we quickly de-risk decision-making in early discoveries and clinical phases (e.g., around targets, indications, MOA, patient stratification), particularly in oncology, autoimmune, and inflammatory diseases & more to come.

The knowing01 core solution is a MultiomicsAI platform+ that is able to redefine how molecular data is used in early-phase drug discovery and clinical phases I/II.

Our partners value the investor-friendly data stories generated through data-rich analysis, demonstrating that everything possible has been done to de-risk an asset.

----------------

Our biotech and pharma partners have seen significant benefits from our ability to reshape existing data and deliver insights for both research and business development—particularly in complex disease areas for example (auto)immune and inflammatory diseases, oncology, and rare diseases.

---------------

The solution – used by biotech and pharma companies – unlocks complex, fragmented Multiomics data through an in silico-first approach:

• Increase early drug discovery success rates

• Seamlessly integrate existing public and private data across all Omics types

• Significantly reduce data analysis time through automation

As a future-proof platform, knowing01 enables continuous data expansion ensuring seamless and sustainable research progress for our long-term partners.

---------------- 

Our innovative technology empowers researchers to maximize the potential of their molecular (often Multiomics) data. We leverage knowledge graphs, machine learning (ML), and artificial intelligence (AI) to establish billions of links in Big Data, transforming raw information into actionable insights.

----------------

## FAQ

How we work? 

1. Automated, structured evidence mapping, helping biotech teams communicate their findings effectively to investors and regulators.

2. Short-term analytics projects or long-term collaborations, adapting to your pipeline needs. 

Which Multiomics layers do we cover?

🧬 Genomics (WGS, WES, rare variants, structural variants) 

🔬 Transcriptomics (RNA-seq, single-cell, bulk, spatial) 

🧫 Proteomics (mass spectrometry, protein expression, PTMs) 

⚙ Epigenomics (methylation, ATAC-seq, histone modifications) 

🔗 Pathway & Network Biology (protein-protein interactions, signaling cascades, disease graphs)

🧪 Metabolomics (small molecules, metabolic pathways, fluxomics) 

🦠 Microbiomics (16S, shotgun metagenomics, host-microbe interactions) 

What to Expect?

• Insights within a week with 5X more data – from raw data to actionable results

• Multiomics integration – from single amino acids to genetic rare variants

• AI-powered analytics – biomarkers, responders/non-responders, disease mechanisms

• Graph-based contextualization – seamless Omics data integration

• No-code, scalable software solution – accessible beyond bioinformatics teams

Outcome?

✅  Stronger data stories. Better decision-making. Faster results.